Role of Anti-TREK-1 Autoantibodies in SCVF
Launched by INSTITUT UNIVERSITAIRE DE CARDIOLOGIE ET DE PNEUMOLOGIE DE QUÉBEC, UNIVERSITY LAVAL · Apr 16, 2025
Trial Information
Current as of June 27, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Please refer to the uploaded study protocol
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years
- • Diagnosis of SCVF as per current criteria
- • Willingness to provide written informed consent
- Exclusion Criteria:
- • - SCVF patients \< age 18
About Institut Universitaire De Cardiologie Et De Pneumologie De Québec, University Laval
The Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ) at Université Laval is a leading academic research institution dedicated to advancing knowledge and clinical practices in cardiovascular and respiratory health. Renowned for its innovative research and comprehensive care, IUCPQ integrates cutting-edge clinical trials with a focus on improving patient outcomes in cardiology and pulmonology. The institution collaborates with a network of healthcare professionals and researchers to explore new therapeutic approaches, enhance clinical guidelines, and contribute to the global body of medical knowledge. With a commitment to excellence in patient care and research, IUCPQ plays a pivotal role in shaping the future of cardiovascular and pulmonary medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Quebec, , Canada
Patients applied
Trial Officials
Christian Steinberg, MD
Principal Investigator
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported